NCT04609540Unknown不适用
Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study
Shandong Cancer Hospital and Institute0 个研究点目标入组 200 人开始时间: 2021年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 200
- 主要终点
- Progression free survival(PFS)
研究概览
简要总结
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •woman, age > 18 years old
- •Diagnosed with HER2 +Metastatic Breast Cancer
- •Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31
- •Available medical history
排除标准
- •Incomplete medical history
研究组 & 干预措施
Pyrotinib and Trastuzumab group
Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
干预措施: Trastuzumab (Drug)
结局指标
主要结局
Progression free survival(PFS)
时间窗: 1 year
The time from starting pyrotinib until disease progression or death from any cause.
次要结局
- Overall survival(OS)(1 year)
- Objective Response Rate(ORR)(1 year)
- Safety(1 year)
研究者
Zhiyong Yu
Principal Investigator
Shandong Cancer Hospital and Institute
相似试验
已完成
不适用
Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer PatientsBreast CancerNCT05839288Fudan University161
Unknown
不适用
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Colorectal CancerNCT03843749Shanghai Changzheng Hospital30
已完成
不适用
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBCBreast CancerNCT04001634Fudan University285
已完成
2 期
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast CancerHER2 Positive Breast CancerNCT02362958Sun Yat-sen University159
尚未招募
2 期
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast CancerBreast Neoplasm FemaleNCT05577442Peking University Cancer Hospital & Institute52